

Table S10. Predictors of EULAR response at 6 and 12 months of treatment with abatacept in rheumatoid arthritis patients (bivariate analysis)

	6 months							12 months					
Clinical variable	EULAR response						Clinical variable	EULAR response					
	N	Unsatisfactory	Satisfactory	p	OR	95% CI		N	Unsatisfactory	Satisfactory	p	OR	95% CI
Sex							Sex						
Women	89	63 (70.8)	26 (29.2)	0.373	–	–	Women	75	45 (60)	30 (40)	0.063	–	–
Men	31	19 (61.3)	12 (38.7)				Men	30	12 (40)	18 (60)			
Smoking							Smoking						
Smoker	18	12 (66.7)	6 (33.3)	0.602	–	–	Smoker	16	7 (43.8)	9 (56.2)	0.594	–	–
Ex-smoker	14	8 (57.1)	6 (42.9)				Ex-smoker	12	6 (50)	6 (50)			
Non-smoker	88	62 (70.5)	26 (29.5)				Non-smoker	77	44 (57.1)	33 (42.9)			
Age at Dx	120	45.22 ± 13.19	45.00 ± 14.97	0.935	–	–	Age at Dx	105	44.53 ± 13.61	46.44 ± 14.64	0.490	–	–
Years with RA	120	17 (12–22)	12 (7.25–18)	0.035	0.94	0.89 – 0.99	Years with RA	105	17 (12–23)	13.5 (8–18.5)	0.064	–	–
ABA start age	120	57.49 ± 12.87	54.76 ± 13.33	0.288	–	–	ABA start age	105	57.44 ± 13.40	56.48 ± 13.49	0.716	–	–
ABA duration	120	23 (13–35.75)	31.5 (16.25–48.75)	0.067	–	–	ABA duration	105	24 (16–44)	30.5 (20–50.5)	0.211	–	–
Administr.							Administr.						
SC	68	43 (63.2)	25 (36.8)	0.235	–	–	SC	60	31 (51.7)	29 (48.3)	0.534	–	–
IV	52	39 (75)	13 (25)				IV	45	26 (57.8)	19 (42.2)			
Concomitant csDMARDs							Concomitant csDMARDs						
MTX	42	30 (71.4)	12 (28.6)	0.592	–	–	MTX	37	20 (54.1)	17 (45.9)	0.998	–	–
LFN	14	8 (57.1)	6 (42.9)				LFN	13	7 (53.8)	6 (46.2)			
none	64	44 (68.8)	20 (31.2)				none	55	30 (54.5)	25 (45.5)			
Concom. GCs							Concom. GCs						

Yes	102	75 (73.5)	27 (26.5)	0.006	4.30	1.36–14.55	Yes	89	53 (59.6)	36 (40.4)	0.010	4.42	1.32–14.78
No	18	7 (38.9)	11 (61.1)				No	16	4 (25)	12 (75)			
Monotherapy							Monotherapy						
No	113	81 (71.7)	32 (28.3)	0.004	14.82	1.69–704.16	No	98	56 (57.1)	42 (42.9)	0.028	7.86	0.93–68.99
Yes	7	1 (14.3)	6 (85.7)				Yes	7	1 (14.3)	6 (85.7)			
Number of previous BTs	120	2 (1–3)	2 (1–3)	0.106	–	–	Number of previous BTs	105	2 (1–3)	2 (1–3)	0.342	–	–
Duration of previous BTs	120	48 (24–84)	24 (9–45)	0.003	0.98	0.97–0.99	Duration of previous BTs	105	48 (24–84)	24 (9–51)	0.071	–	–
Previous BTs							Previous BTs						
Naive	15	7 (46.7)	8 (53.3)	0.271	–	–	Naive	14	3 (21.4)	11 (78.6)	0.028	0.17	0.03–0.71
1 TNFi	31	21 (67.7)	10 (32.3)				1 TNFi	28	17 (60.7)	11 (39.3)			
2 TNFis	34	25 (73.5)	9 (26.5)				2 TNFis	31	21 (67.7)	10 (32.3)			
3 or more TNFis	40	29 (72.5)	11 (27.5)				3 or more TNFis	32	16 (50)	16 (50)			
RF							RF						
Negative	24	16 (66.7)	8 (33.3)	0.844	–	–	Negative	22	11 (50)	11 (50)	0.649	–	–
Positive	96	66 (68.8)	30 (31.2)				Positive	83	46 (55.4)	37 (44.6)			
ACPA							ACPA						
Negative	35	28 (80)	7 (20)	0.088	–	–	Negative	30	16 (53.3)	14 (46.7)	0.901	–	–
Positive	85	54 (63.5)	31 (36.5)				Positive	75	41 (54.7)	34 (45.3)			
DAS28	120	5.14 ± 1.18	3.74 ± 1.47	<0.001	0.42	0.90 – 1.89	DAS28	105	4.95 ± 1.07	4.25 ± 1.63	0.013	0.68	0.49–0.91
Baseline NPJ	120	8 (4–11)	3 (0.25–6)	<0.001	0.84	0.75–0.92	Baseline NPJ	105	7 (4–10)	4.5 (2–8.25)	0.026	0.94	0.87–1.01
Baseline NSJ	120	3.5 (1–6)	1 (0–3)	<0.001	0.79	0.67–0.91	Baseline NSJ	105	3 (2–5)	1.5 (0–5)	0.103	–	–
PVAS	120	70 (60–80)	50 (22.5–60.0)	<0.001	0.94	0.92–0.97	PVAS	105	70 (60–80)	50 (30–70)	<0.001	0.95	0.93–0.97
Baseline CRP	120	2 (1–3.89)	2.55 (1.11–4.85)	0.394	–	–	Baseline CRP	105	2 (1–4.3)	2.04 (1.08–3.93)	0.992	–	–

Baseline ESR	120	27 (14–44.5)	14 (8–30)	0.010	0.97	0.94–0.99	Baseline ESR	105	22 (12–45)	21 (9.75–34.5)	0.387	–	–
HAQ	120	1.75 (1.50–2.00)	1.20 (0.75–1.73)	<0.001	0.32	0.16–0.58	HAQ	105	1.75 (1.25–2)	1.25 (0.75–2)	0.002	0.39	0.21–0.71
FCGR2A rs1801274							FCGR2A rs1801274						
AA	38	21 (55.3)	17 (44.7)	0.058	–	–	AA	35	22 (62.9)	13 (37.1)	0.352	–	–
GG	29	24 (82.8)	5 (17.2)				GG	25	14 (56)	11 (44)			
AG	53	37 (69.8)	16 (30.2)				AG	45	21 (46.7)	24 (53.3)			
A	91	58 (63.7)	33 (36.3)	0.067	–	–	A	80	43 (53.8)	37 (46.2)	0.844	–	–
G	82	61 (74.4)	21 (25.6)	0.056	–	–	G	70	35 (50)	35 (50)	0.299	–	–
FCGR3A rs396991							FCGR3A rs396991						
CC	22	17 (77.3)	5 (22.7)	0.615	–	–	CC	21	15 (71.4)	6 (28.6)	0.162	–	–
AA	29	20 (69)	9 (31)				AA	23	10 (43.5)	13 (56.5)			
CA	69	45 (65.2)	24 (34.8)				CA	61	32 (52.5)	29 (47.5)			
C	91	62 (68.1)	29 (31.9)	0.933	–	–	C	82	47 (57.3)	35 (42.7)	0.344	–	–
A	98	65 (66.3)	33 (33.7)	0.448	–	–	A	84	42 (50)	42 (50)	0.078	–	–
Low-affinity allele FCGR2A/FCGR3A	120	2 (1–3)	2 (1–2)	0.155	–	–	Low-affinity allele FCGR2A/FCGR3A	105	2 (1–2)	2 (1.75–3)	0.088	–	–

ABA: abatacept; ACPA: anti-citrullinated protein antibody; AR: adverse reaction; BT: biological therapy; CI: confidence interval; CRP: C-reactive protein; csDMARD: conventional synthetic disease-modifying antirheumatic drug; DAS28: disease activity score in 28 joints; Dx: diagnosis; ESR: erythrocyte sedimentation rate; EULAR: European League Against Rheumatism criteria; GC: glucocorticoid; HAQ: Health Assessment Questionnaire; IV: intravenous; LFN: leflunomide; MTX: methotrexate; NPJ: number of painful joints; NSJ: number of swollen joints; OR: odds ratio; PVAS: patient visual analogue scale; RA: rheumatoid arthritis; RF: rheumatoid factor; SC: subcutaneous; SD: standard deviation; TNFi: tumor necrosis factor inhibitor.